Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	PIK-93	1	72	sigmoid	sigmoid	BT20 PIK-93 0 1 72	8	2.025	2.65	0.406	0.0864	6.54	-1.0	1.22	0.993	3.89e-07	NA	3.15	0.49	0.92	3.15	0.0	1.31	0.989	1.33e-06	NA
BT-20	MK2206	2	72	sigmoid	sigmoid	BT20 MK-2206 0 2 72	8	1.739	0.823	0.0896	0.246	4.34	-1.0	0.661	0.965	4.36e-05	NA	1.47	0.348	0.806	1.47	0.0	0.715	0.947	0.000145	NA
HCC70	Dactolisib	1	72	sigmoid	sigmoid	HCC70 dactolisib 0 1 72	8	1.400	0.0808	-0.0667	0.501	3.34	-1.0	0.295	0.963	5.02e-05	NA	0.753	0.344	0.673	0.753	0.0	0.308	0.962	5.37e-05	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
BT-549	Buparlisib	1	72	sigmoid	sigmoid	BT549 buparlisib 0 1 72	8	1.837	0.729	-0.325	0.253	1.83	-1.0	1.19	0.994	2.4e-07	NA	0.926	0.136	0.807	0.926	0.0	1.37	0.987	2.46e-06	NA
Hs 578T	Omipalisib	1		sigmoid	sigmoid	Hs578T omipalisib 1	8	2.079	0.00552	-0.546	0.842	0.17	-1.0	0.321	0.98	8.1e-06	NA	0.0079	0.0459	0.351	0.0079	0.0	0.369	0.984	4.12e-06	NA
Hs 578T	Omipalisib	2		sigmoid	sigmoid	Hs578T omipalisib 2	8	2.507	0.0155	-0.52	0.766	0.239	-1.0	0.402	0.993	3.45e-07	NA	0.0114	0.028	0.355	0.0114	0.0	0.468	0.981	6.9e-06	NA
BT-20	Pictilisib	2	72	sigmoid	sigmoid	BT20 pictilisib 0 2 72	8	1.746	0.308	-0.0521	0.379	2.35	-1.0	0.54	0.791	0.00908	NA	0.634	0.272	0.712	0.634	0.0	0.6	0.716	0.0229	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-549	Buparlisib	3	72	sigmoid	sigmoid	BT549 buparlisib 0 3 72	8	1.795	0.602	-0.351	0.295	1.64	-1.0	1.09	0.983	4.52e-06	NA	0.804	0.132	0.777	0.804	0.0	1.26	0.968	3.41e-05	NA
BT-20	Pictilisib	1	72	sigmoid	sigmoid	BT20 pictilisib 0 1 72	8	2.085	1.25	0.163	0.177	5.0	-1.0	0.791	0.994	1.75e-07	NA	1.52	0.323	0.838	1.52	0.0	0.865	0.989	1.22e-06	NA
Hs 578T	PIK-93	1		sigmoid	sigmoid	Hs578T PIK-93 1	8	2.033	1.44	0.276	0.175	8.38	-1.0	0.624	0.991	6.57e-07	NA	2.0	0.401	0.84	2.0	0.0	0.672	0.99	9.72e-07	NA
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	AZD-6482	1	72	flat	flat	HCC1806 AZD6482 0 1 72	8	2.748	Inf	1.0	0.00141	0.0	1.0	0.01	-0.00621	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)